Indications for ADHANSIA XR:
Attention deficit hyperactivity disorder.
Adults and Children:
<6yrs: not established. Swallow whole, or may open caps and sprinkle contents onto applesauce/yogurt (swallow immediately); do not crush, chew, or divide beads. Individualize. ≥6yrs: initially 25mg once daily in the AM. May titrate by 10–15mg at intervals of ≥5 days; max 100mg/day (adults) or 85mg/day (children). Switching from other methylphenidate products: discontinue and follow Adhansia XR titration schedule. Not interchangeable on a mg-per-mg basis.
During or within 14 days of MAOIs.
Abuse and dependence.
High potential for abuse and dependence: monitor. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors of developing a manic episode prior to initiation. Consider discontinuing if new psychotic/manic symptoms occur. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Allergic reactions (tartrazine). Aspirin hypersensitivity. Reevaluate periodically. Pregnancy. Nursing mothers: monitor infants.
See Contraindications. Hypertensive crisis with MAOIs (eg, selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue). Efficacy may be affected with concomitant gastric pH modulators (eg, omeprazole, esomeprazole, pantoprazole, famotidine, sodium bicarbonate): monitor and use alternative based on response. Avoid alcohol.
Insomnia, dry mouth, decreased appetite, nausea, vomiting, weight loss, upper abdominal pain, feeling jittery, irritability, dizziness; hypertension, tachycardia, priapism, peripheral vasculopathy, growth suppression, psychiatric reactions.
Register pregnant patients in the National Pregnancy Registry for Psychostimulants by calling (866) 961-2388.